Features | Partner Sites | Information | LinkXpress
Sign In
Bio-Rad Diabetes Division
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Ceramides in Blood Predict Risk of Alzheimer's Disease

By Labmedica International staff writers
Posted on 31 Jul 2012
High levels of ceramides, a family of lipids, in the blood of a patient may be predictive of developing Alzheimer's disease.

Dr. Mielke PhD, from the Mayo Clinic (Rochester, MN, USA) and her team conducted a study to see whether blood levels of ceramides and sphingomyelins are associated with increased risk of Alzheimer's disease (AD). Previous studies found links between high serum ceramide levels and memory impairment and hippocampal volume loss.

Participants in a longitudinal, population-based study included healthy women 70 to 80 years of age, living in Baltimore, (Maryland, USA). None had dementia at baseline. The women were followed for up to six visits over nine years. Their blood was collected at baseline and at each subsequent visit. Out of 99 women, 27 (27.3%) developed incident dementia. Of these, 18 (66.7%) were diagnosed with probable Alzheimer's disease.

An increased risk of Alzheimer's disease was associated with higher baseline serum ceramides. However, higher levels of sphingomyelins were not linked to increased Alzheimer's disease risk. The team also noted that women in the middle tertile of serum ceramide levels had the highest risk for Alzheimer's versus those in the lowest tertile, with an intermediate increased risk seen among those in the highest tertile.

Michelle M. Mielke said, "The study is small—that's a limitation, and it was a preliminary study. However, given the small sample size, to have hazard ratios that are near 10 was quite striking and we didn't expect to see that at all," said Dr. Mielke. "Pretty much any marker is not going to be associated with a 10-fold risk, so yes, this does need to be replicated in another study, but it suggests to us that plasma or blood ceramide levels are associated with an increased risk of Alzheimer's disease," she said.

According to Valory Pavlik, PhD, of the Alzheimer's disease and memory disorders center at Baylor College of Medicine (Houston, TX, USA) the study findings are noteworthy. Identification of an accurate biomarker to predict Alzheimer's disease that can be obtained with a minimum of cost and inconvenience to a patient, could lead to model focused on preventing or delaying disease onset.

Related Links:
Mayo Clinic
Baylor College of Medicine



DiagCor Bioscience
PURITAN MEDICAL
77 ELEKTRONIKA
comments powered by Disqus
Life Technologies

Channels

Genetic Tests

view channel
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).

Promising Blood Biomarkers Isolated for Colorectal Cancer

The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.... Read more

Microbiology

view channel
Image: The causative parasite of Chagas disease Trypanosoma cruzi in a blood film (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Undiagnosed Chagas Disease Emerging as Public Health Threat

Chagas disease or American trypanosomiasis is typically spread to people through the feces of blood-sucking triatomine bugs sometimes called kissing bugs because they feed on people's faces during the night.... Read more

Industry News

view channel

Oncology Companion Diagnostics Sector Grows to Over USD 1 Billion

The market for diagnostic test and pharmaceutical drug pairs for cancer treatment has grown significantly, according to the report “Companion Diagnostic Markets” from healthcare market research firm Kalorama Information (New York City, NY, USA). The global companion diagnostics (CDx) market is valued at about USD 1.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.